128 results on '"Damjanov, N"'
Search Results
2. POS1280 CIRCULATING EXTRACELLULAR VESICLES AS A POTENTIAL BIOMARKER OF INTERSTITIAL LUNG DISEASE AND ITS PROGRESSION IN SYSTEMIC SCLEROSIS –A PROSPECTIVE COHORT STUDY
3. POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
4. 59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
5. Abstract No. 28 Radiosensitization for TARE: does duration of chemotherapy affect PFS?
6. Abstract No. 246 CapTemY90 for grade 2 liver-dominant NET metastases
7. AB0889 Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 Trial
8. AB0350 ASSESSMENT OF REAL-LIFE PATIENT HANDLING EXPERIENCE OF AVT02 ADMINISTERED SUBCUTANEOUSLY VIA AUTOINJECTOR IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: AN OPEN-LABEL, SINGLE-ARM CLINICAL TRIAL, THEN AN EXTENSION PHASE OF AVT02 ADMINISTERED WITH A PRE-FILLED SYRINGE (ALVOPAD-PEN)
9. POS0383 CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE.
10. POS0923 EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKERS OF EARLY DISEASE STAGE IN SYSTEMIC SCLEROSIS
11. Corrélation entre amélioration des résultats rapportés par le patient (PRO) et mesures strictes de l’activité de la maladie chez des patients atteints de rhumatisme psoriasique et traités par upadacitinib versus placebo ou adalimumab
12. 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
13. OP0074 A FRAMEWORK OF POTENTIAL INTERVENTIONS TO ACCELERATE GENDER-EQUITABLE CAREER ADVANCEMENT IN ACADEMIC RHEUMATOLOGY
14. POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE
15. POS0874 CLOT LYSIS TIME PREDICTS RECURRENT DIGITAL ULCERS IN SYSTEMIC SCLEROSIS AFTER ONE YEAR OF FOLLOW-UP: A NESTED CASE-CONTROL STUDY
16. 45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
17. OP0317 ACCURACY OF THE OMERACT DEFINITIONS FOR IDENTIFICATION OF CALCIUM PYROPHOSPHATE CRYSTALS WITH ULTRASOUND: FINAL RESULTS OF THE OMERACT US IN CPPD SUB-TASK FORCE STUDY
18. AB0663 EFFICACY OF BIOLOGICAL THERAPY IN TREATMENT OF ANKYLOSING SPONDYLITIS IN SERBIA
19. THU0653-HPR BARRIERS FOR THE UPTAKE OF EULAR POSTGRADUATE EDUCATION FOR HEALTH PROFESSIONALS IN RHEUMATOLOGY IN EASTERN EUROPEAN COUNTRIES: RESULTS FROM 3 NATIONAL SURVEYS
20. THU0109 DOES HIGH BASELINE LEVEL OF MATRIX METALLPROTEINASES 3 (MMP3) INDICATE MORE MTP5 JOINT EROSIONS IN EARLY RHEUMATOID ARTHRITIS PATIENTS? (THE 2-YEAR PROSPECTIVE ULTRASONOGRAPHIC STUDY)
21. SAT0050 PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA)
22. FRI0232 ALTERED FIBRIN CLOT PROPERTIES IN PATIENTS WITH SYSTEMIC SCLEROSIS
23. FRI0138 THE IMPACT OF UPADACITINIB VERSUS METHOTREXATE OR ADALIMUMAB ON INDIVIDUAL AND COMPOSITE DISEASE MEASURES IN PATIENTS WITH RHEUMATOID ARTHRITIS
24. OP0117 LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL
25. AB1202 IMPACT OF BIOLOGICAL THERAPY ON WORK ABILITY AND PRODUCTIVITY IN RHEUMATOID ARTHRITIS
26. OP0218 CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL
27. THU0213 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
28. THU0580 EULAR TASK FORCE ON GENDER EQUITY IN ACADEMIC RHEUMATOLOGY: PRELIMINARY SURVEY FINDINGS
29. AB0600 THE EFFECTS OF HYPERBARIC OXYGEN THERAPY TO QUALITY OF LIFE AND STATE OF MICROCIRCULATION IN PATIENTS WITH SYSTEMIC SCLEROSIS - A PILOT STUDY
30. Anatomical and ultrasound navigation of intra joint injections
31. Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
32. Effect of golimumab on endothelial vasomotor function and arterial stiffness in ankylosing spondylitis
33. Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database
34. EFFECT OF GOLIMUMAB ON IMMUNOLOGICAL MARKERS FOR BONE METABOLISM AND ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
35. FRI0467 The relationship between 99mtc-pertechnetate hand perfusion scintigraphy and naifolid capilloscopy in systemic sclerosis patients: a pilot study
36. AB0307 Predictive value of the baseline clinical, laboratory and echosonographic parameters of ra activity in progression of structural damage in dmards naÏve early ra patients – 6 months follow-up-
37. AB1040 Is gout a chronic inflammatory disease of a low level of activity?
38. SAT0461 Ultrasonography of salivary glands in primary sjogren’s syndrome and association with disease activity, serological markers and biopsy of minor salivary glands
39. AB0079 Alfacalcidol suplementation modulates cytokine production in peripheral blood mononuclear cells culture of patients with active rheumatoid arthritis
40. 3:36 PM Abstract No. 265 Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors (CapTemY90): final report
41. There is a need for new systemic sclerosis subset criteria. A content analytic approach
42. Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control with Low Toxicity
43. High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data
44. SAT0378 Bone marrow oedema and synovitis on MRI of the hand are associate with digital ulcers, active disease and impaired functional capacity in systemic sclerosis
45. FRI0637 Diagnostic performance of the new omeract criteria for cppd identification by us: correlation with synovial fluid analysis
46. THU0292 Diagnostic accuracy of ultrasound and ultrasonographic features of salivary glands in patients with primary sjogren's syndrome
47. SAT0648 Ultrasound findings in symptomatic and asymptomatic joints in patients with gout
48. SAT0636 Ultrasonography definitions for synovitis grading in children: the omeract pediatric ultrasound task force
49. SAT0064 High MMP3 serum levels are associated with extensive structural damage in patients with early, treatment naive rheumatoid arthritis (RA): two years prospective clinical and ultrasonographic study
50. AB0103 Humoral Immunity To Food Antigens in Patients with Early Steroid and BMARD Naïve Rheumatoid Arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.